Ctrl Worx Watch List › Company

BioRegenx, Inc. (BRGX): material weakness open 1,855 days

By , Ctrl Worx™. Built from its own SEC filings. How the Clock works.

BioRegenx, Inc. reported ineffective internal control over financial reporting because of a material weakness in 18 filings since Nov 22, 2021. It stated one or more material weaknesses in 4 more SEC filings that gave no conclusion on whether that control is effective. The latest was its 10-Q for the period ended Mar 31, 2026.

Ctrl Worx Watch List™ status

On the Clock
5.1 yearsopen since Sep 30, 2021
10-Q, May 20, 2026latest filing that reports the weakness. Read it on SEC EDGAR
#390 of 1,250on the Clock by time open, tied with 22 other companies that share its start date. See the Clock

Still filing, and no annual report of its own says the weakness is fixed.

Checked against SEC EDGAR: Oct 29, 2026 · Entry #11061

Filings with a weakness22
First in our dataNov 22, 2021
AuditorWeinberg & Company, P.A.

Causes the company named

Entity-level and governance · 22Financial close and reporting · 21Accounting expertise and resources · 18Segregation of duties · 17ITGC: general · 7

Insufficient personnel, inadequate segregation of duties, weak control environment, and ineffective financial close controls.

What the latest filing says

not effective as of March 31, 2026 due to the material weaknesses in our intenal control over financial reporting described below. Disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time period specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management, including the CEO and CFO, as appropriate, to allow timely decisions regarding required disclosures. Our management necessarily applied its judgment in assessing the costs and benefits of such controls and procedures, which, by their nature, can provide only reasonable assurance regarding management’s control objectives. Our management, with the participation of our CEO, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the period ended March 31, 2026. Based upon this evaluation, our CEO concluded that our disclosure controls and procedures were not effective bec [...]

From the controls section of the 10-Q filed May 20, 2026. Read the full filing on SEC EDGAR.

Company response: BioRegenx, Inc. can send a statement or a link to its remediation update to russell@ctrlworx.com. We post it here, unedited and dated.

Filings

FiledFormPeriodControlsCausesFiling
May 20, 202610-QMar 31, 2026Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reporting; Accounting expertise and resources; Entity-level and governanceEDGAR
Apr 15, 202610-KDec 31, 2025Not effectiveSegregation of duties; Financial close and reporting; Accounting expertise and resources; Entity-level and governanceEDGAR
Nov 14, 202510-QSep 30, 2025Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reporting; Accounting expertise and resources; Entity-level and governanceEDGAR
Aug 14, 202510-QJun 30, 2025Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reporting; Accounting expertise and resources; Entity-level and governanceEDGAR
May 15, 202510-QMar 31, 2025Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reporting; Accounting expertise and resources; Entity-level and governanceEDGAR
Apr 16, 202510-K/ADec 31, 2024Not effectiveSegregation of duties; Financial close and reporting; Accounting expertise and resources; Entity-level and governanceEDGAR
Apr 15, 202510-KDec 31, 2024Not effectiveSegregation of duties; Financial close and reporting; Accounting expertise and resources; Entity-level and governanceEDGAR
Nov 14, 202410-QSep 30, 2024Not effectiveSegregation of duties; Financial close and reporting; Accounting expertise and resources; Entity-level and governanceEDGAR
Oct 9, 202410-QJun 30, 2024Not effectiveSegregation of duties; Financial close and reporting; Accounting expertise and resources; Entity-level and governanceEDGAR
Oct 9, 202410-Q/AMar 31, 2024Not effectiveSegregation of duties; Financial close and reporting; Accounting expertise and resources; Entity-level and governanceEDGAR
May 29, 202410-Q/AMar 31, 2024Not effectiveSegregation of duties; Financial close and reporting; Accounting expertise and resources; ITGC: general; Entity-level and governanceEDGAR
May 24, 202410-QMar 31, 2024Not effectiveSegregation of duties; Financial close and reporting; Accounting expertise and resources; ITGC: general; Entity-level and governanceEDGAR
Apr 12, 202410-KDec 31, 2023Not effectiveSegregation of duties; Financial close and reporting; Accounting expertise and resources; ITGC: general; Entity-level and governanceEDGAR
Nov 20, 202310-QSep 30, 2023Not effectiveSegregation of duties; Financial close and reporting; Accounting expertise and resources; ITGC: general; Entity-level and governanceEDGAR
Aug 15, 202310-QJun 30, 2023Not effectiveSegregation of duties; Financial close and reporting; Accounting expertise and resources; ITGC: general; Entity-level and governanceEDGAR
May 22, 202310-QMar 31, 2023Not effectiveSegregation of duties; Financial close and reporting; Accounting expertise and resources; ITGC: general; Entity-level and governanceEDGAR
Apr 4, 202310-KDec 31, 2022Not effectiveSegregation of duties; Financial close and reporting; Accounting expertise and resources; ITGC: general; Entity-level and governanceEDGAR
Nov 21, 202210-QSep 30, 2022Not effectiveAccounting expertise and resources; Entity-level and governanceEDGAR
Aug 12, 202210-QJun 30, 2022Not effectiveFinancial close and reporting; Entity-level and governanceEDGAR
May 23, 202210-QMar 31, 2022Not effectiveFinancial close and reporting; Entity-level and governanceEDGAR
Apr 13, 202210-KDec 31, 2021Not effectiveFinancial close and reporting; Entity-level and governanceEDGAR
Nov 22, 202110-QSep 30, 2021Not effectiveFinancial close and reporting; Entity-level and governanceEDGAR

Others on the Clock in the same industry

By SEC industry code: 7370, Services-Computer Programming, Data Processing, Etc., then related codes.

Follow BRGX for free

Get an email when BioRegenx, Inc files a 10-K or 10-Q that reports a material weakness, or says its controls are effective again.

Want the next one the day it's filed?

MW Pro sends an alert the day a company you follow reports a material weakness or says it fixed one. Founding price $990 a year.

Join the MW Pro waitlistLook up any company in Controls Radar™

Watch List Weekly: new material weaknesses, fixes and the longest-running cases, every Monday.

One email to confirm, then one email each Monday. Every email has a one-click unsubscribe. Privacy policy

Based on public SEC filings. Causes are grouped into standard categories by Ctrl Worx. The filings are the authority. Ctrl Worx is not affiliated with BioRegenx, Inc. or the SEC. Not investment advice. Why you can rely on the Watch List.